Cargando…

DNA damaging agents in ovarian cancer

Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agen...

Descripción completa

Detalles Bibliográficos
Autor principal:	Barretina-Ginesta, Maria-Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573464/ https://www.ncbi.nlm.nih.gov/pubmed/33240444 http://dx.doi.org/10.1016/j.ejcsup.2020.06.001

Ejemplares similares

Rare ovarian tumours. Other treatments for ovarian cancer
por: Gil-Martin, Marta, et al.
Publicado: (2020)

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
por: Fernández-Serra, Antonio, et al.
Publicado: (2023)

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2017)

Management of advanced ovarian cancer in Spain: an expert Delphi consensus
por: Redondo, Andres, et al.
Publicado: (2021)

Esophageal Infiltration by High-Grade Serous Ovarian Carcinoma: A Very Rare Case Report
por: Carbó-Bagué, Anna, et al.
Publicado: (2023)

SEOM clinical guideline in ovarian cancer (2020)
por: Redondo, A., et al.
Publicado: (2021)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
por: Redondo, Andrés, et al.
Publicado: (2023)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery
por: Plaja, Andrea, et al.
Publicado: (2023)

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2013)

Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer
por: Rabinowicz, Noa, et al.
Publicado: (2017)

Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
por: Bednarikova, Marketa, et al.
Publicado: (2022)

SEOM-GEICO clinical guidelines on endometrial cancer (2021)
por: Barretina-Ginesta, María Pilar, et al.
Publicado: (2022)

Erratum to: Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2016)

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
por: Woopen, Hannah, et al.
Publicado: (2023)

Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells
por: Lamboy-Caraballo, Rocio, et al.
Publicado: (2020)

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models
por: Vena, Francesca, et al.
Publicado: (2018)

DNA damage repair in ovarian cancer: unlocking the heterogeneity
por: Gee, Mary Ellen, et al.
Publicado: (2018)

Combating resistance to DNA damaging agents
por: Choi, Jung-Suk, et al.
Publicado: (2018)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
por: Barretina-Ginesta, Maria-Pilar, et al.
Publicado: (2022)

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
por: Kubelac, Paul, et al.
Publicado: (2020)

Cancer Cells Upregulate Tau to Gain Resistance to DNA Damaging Agents
por: Rico, Thomas, et al.
Publicado: (2022)

Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair
por: Ovejero-Sánchez, María, et al.
Publicado: (2021)

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
por: Oaknin, Ana, et al.
Publicado: (2020)

DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
por: Ovejero-Sánchez, María, et al.
Publicado: (2023)

DNA Damage Induced by Alkylating Agents and Repair Pathways
por: Kondo, Natsuko, et al.
Publicado: (2010)

Silencing Artemis Enhances Colorectal Cancer Cell Sensitivity to DNA-Damaging Agents
por: Liu, Hai, et al.
Publicado: (2018)

Response of the Green Alga Chlamydomonas reinhardtii to the DNA Damaging Agent Zeocin
por: Čížková, Mária, et al.
Publicado: (2019)

SEOM Clinical Guideline in ovarian cancer (2016)
por: Santaballa, A., et al.
Publicado: (2016)

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
por: Rubio, María Jesús, et al.
Publicado: (2020)

Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells
por: Xu, Li, et al.
Publicado: (2019)

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents
por: Murray, Clare, et al.
Publicado: (2022)

Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer
por: Jin, Yimei, et al.
Publicado: (2016)

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
por: Bouberhan, Sara, et al.
Publicado: (2023)

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2015)

The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
por: Yeo, Xun Hui, et al.
Publicado: (2023)

Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers
por: Lee, Yoo-Kyung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ul4o638b7c3v2ie4otq517cflr